NPCE NASDAQ
NeuroPace, Inc.
1W: -3.6%
1M: -8.0%
3M: -4.5%
YTD: -14.2%
1Y: +24.2%
3Y: +89.2%
5Y: -15.8%
$13.02
+0.03 (+0.23%)
Weekly Expected Move ±6.9%
$11
$12
$13
$14
$15
Credit Risk of going bust: higher than 54% of companies Debt: 13.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.20 (down 98%), NeuroPace, Inc. would be worth roughly what it owes.
Total debt $69.9M against a stock market value of $446.9M.
Distance to default 4.77 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $29.5M (short-term plus half of long-term), stock volatility 59.4%; Altman Z -3.60. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.20 (down 98%), NeuroPace, Inc. would be worth roughly what it owes.
Total debt $69.9M against a stock market value of $446.9M.
Distance to default 4.77 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $29.5M (short-term plus half of long-term), stock volatility 59.4%; Altman Z -3.60. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (57)
NeuroPace, Inc. (NASDAQ:NPCE) Stock Has Consensus Price Target of $19.33 According to Analysts
Bank of America Corp DE Sells 145,741 Shares of NeuroPace, Inc. $NPCE
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc.
NeuroPace, Inc. (NASDAQ:NPCE) Receives $19.29 Average Price Target from Brokerages
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates
CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?
NPCE Explains How NeuroPace's RNS System Makes Money
NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care
NeuroPace (NPCE) Q1 2026 Earnings Transcript
NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised
Neuropace signals $99M-$101M 2026 revenue outlook while targeting 21%-23% underlying RNS growth
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
Earnings Scheduled For May 12, 2026
BSX Q1 Neuromodulation Sales Rise 15% Y/Y: What Lies Behind the Growth?
NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages
12 Health Care Stocks Moving In Monday's Pre-Market Session
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026
NPCE RNS System Explained: Growth Drivers and Setup for 2026
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand
Analysts Set NeuroPace, Inc. (NASDAQ:NPCE) PT at $18.67
Why NeuroPace Stock Was Inching Higher on Wednesday
NeuroPace reiterates $98M–$100M 2026 revenue target while advancing AI and IGE pipeline
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates
NeuroPace GAAP EPS of -$0.08 beats by $0.08, revenue of $26.6M beats by $1.81M
Earnings Summary: NeuroPace Q4
Earnings Scheduled For March 3, 2026
Earnings Outlook For NeuroPace
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of “Moderate Buy” from Brokerages
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
NeuroPace (NASDAQ:NPCE) and Envoy Medical (NASDAQ:COCH) Critical Comparison
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services